Proton beam radiation
RadiationOnce per day, 5 days a week for a total of 4 to 6 weeks.
NCT Number: NCT00592293
The main purpose of this study is to assess the short term and the long term side effects of proton beam radiation for pediatric bone and non-rhabdomyosarcoma soft tissue sarcomas.
Looking for future studies?
Notify MeUp to 30 year
All sexes
Interventional
Not applicable
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Once per day, 5 days a week for a total of 4 to 6 weeks.
Time frame: 5 years from the completion of radiation treatment
Cumulative incidence (percent of participants and 95% confidence intervals) who experienced a grade 3, 4, or 5 late toxicity. Late complications are defined as the delayed effects attributable to radiation which occur > 90 days following completion of radiation.
Time frame: 5 years from the start of radiation treatment
Rates of local control using proton radiotherapy. Local control is the lack of tumor recurrence in and or near the area where the primary tumor occurred.
Time frame: 5 years
Comparison of Dose distribution to tumor and surrounding normal structures using Dose-Volume Histograms (DVH) generated from the proton plan used to treat the patient and the photon plan generated for comparison purposes.
Massachusetts General Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03441360
Ewing Sarcoma, Myosarcoma
Birmingham, Alabama, United States
View Trial DetailsNCT03245450
Ewing Sarcoma, Myosarcoma
Marseille, Bouches-du-Rhône, France
View Trial DetailsNCT02390843
Adenocarcinoma, Carcinoma
Atlanta, Georgia, United States
View Trial DetailsNCT00165139
Ewings Sarcoma, Neoplasms
Boston, Massachusetts, United States
View Trial Details